MEDI 23-Multivalent muscarinic antagonists for the treatment of overactive bladder (OAB)

被引：0
|
作者：
Hughes, Adam D. [1 ]
Chin, Kay H. [2 ]
Hegde, Sharath S. [3 ]
Husfeld, Craig O. [1 ]
Jasper, Jeffrey R. [2 ]
Ji, Yuhua [1 ]
King, Kristin E. [2 ]
Lee, Tae Weon [2 ]
Li, Li [1 ]
Mammen, Mathai [2 ]
McNamara, Alexander J. [3 ]
Mischki, Trevor K. [1 ]
Obedencio, Glenmar P. [3 ]
Pulido-Rios, Tess [3 ]
Steinfeld, Tod [2 ]
Sweazey, Shelley M. [3 ]
Wilson, Richard D. [1 ]
机构：
[1] Theravance Inc, Med Chem, San Francisco, CA 94080 USA
[2] Theravance Inc, Mol & Cellular Biol, San Francisco, CA 94080 USA
[3] Theravance Inc, Pharmacol, San Francisco, CA 94080 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 234卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
23-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Comparison of Two Selective Muscarinic Receptor Antagonists (Solifenacin and Darifenacin) in Women with Overactive Bladder - the SOLIDAR Study
    But, Igor
    Goldstajn, Marina Sprem
    Oreskovic, Slavko
    COLLEGIUM ANTROPOLOGICUM, 2012, 36 (04) : 1347 - 1353
  • [42] Darifenacin -: An M3-selective muscarinic antagonist for the treatment of overactive bladder
    Kirwin, JL
    FORMULARY, 2004, 39 (06) : 291 - +
  • [43] A BLADDER INJECTION SYSTEM AND A SPECIFIC INJECTION PROTOCOL REDUCE URINARY RETENTION FOLLOWING ONABOTULINUMTOXINA TREATMENT OF OVERACTIVE BLADDER (OAB)
    Smith, John
    Proctor, Jeffrey
    MacDiarmid, Scott
    Jacobs, Bradley
    Gywnn, Eric
    Green, Lonny
    JOURNAL OF UROLOGY, 2020, 203 : E910 - E910
  • [44] The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron - a new selective β3agonist
    Rechberger, Tomasz
    Kulik-Rechberger, Beata
    Miotla, Pawel
    Wrobel, Andrzej
    GINEKOLOGIA POLSKA, 2014, 85 (03) : 214 - 219
  • [45] MEDI 200-Alkyne-quinuclidine derivatives as potent and selective muscarinic antagonists for the treatment of COPD
    Provins, Laurent
    Guyaux, Michel
    Mercier, Joel
    Christophe, Bernard
    Gillard, Michel
    Jadot, Sophie
    Lo Brutto, Patrick
    Quere, Luc
    Starck, Jean-Philippe
    Talaga, Patrice
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [46] SAFETY AND PERFORMANCE OF A WIRELESS IMPLANTABLE TIBIAL NERVE STIMULATOR DEVICE FOR THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)
    Elneil, S.
    Digesu, A.
    van Breda, H.
    Heesakkers, J.
    Van Kerrebroeck, P.
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 : S45 - S46
  • [47] Patient satisfaction: Psychometric validation of the OAB-S, an overactive bladder treatment satisfaction questionnaire.
    Piault, EC
    Evans, C
    Marcucci, G
    Kopp, Z
    Brubaker, L
    Abrams, P
    VALUE IN HEALTH, 2005, 8 (06) : A88 - A88
  • [48] COST EFFECTIVENESS OF SOLIFENACIN COMPARED WITH ORAL ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK
    Kelleher, C.
    Aballea, S.
    Maman, K.
    Nazir, J.
    Hakimi, Z.
    Chambers, C.
    Odeyemi, I. A.
    VALUE IN HEALTH, 2014, 17 (07) : A469 - A469
  • [49] Darifenacin:: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder
    Zinner, Norman
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (04) : 511 - 523
  • [50] Overactive bladder symptom scores (OABSS) responsiveness before and after anticholinergic treatment in women with overactive bladder (OAB): The pilot study (vol 43, pg 1189, 2017)
    Bunyavejchevin, S.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (10) : 2003 - 2003
12345